Comparative characteristics of some haematological and biochemical indicators in II–III stages cervix cancer patients with late radiation complications in treatment dynamics

  • V. S. Sevastianova State Organization «Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine»
  • F. V. Hladkykh State Organization «Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine»
  • H. V. Kulinich State Organization «Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine»
Keywords: locally advanced cervical cancer, radiation therapy, late radiation complications

Abstract

Depending on the stage of the process, tactics for the treatment of cervical cancer (СС) may include surgical treatment, radiation therapy (RT), chemotherapy, hormone therapy and a combination of these methods. The leading place in the treatment of patients with cancer is today occupied by combined RT. However, despite improvements in methodological approaches to RT, the problem of side effects of radiation treatment – early and late radiation complications (LRC) still remains to be fully resolved.

Purpose of the study. To carry out comparative analysis of individual hematological and biochemical parameters of peripheral blood (hematocrit, fibrinogen, aspartate aminotransferase (AsAt, urea and total protein) of patients with II and III stage of CC before and after RT.

Materials and methods. A retrospective analysis of case histories of patients with stage II–III cervical cancer was performed. The main group – 102 people: 68 patients with stage II cervical cancer and 34 patients with stage III cervical cancer with LRC. Control group: 90 people – 46 patients with stage II cervical cancer and 44 patients with stage III cervical cancer without LRC.

Results. The study showed that in patients with СС with LRC were higher baseline (before RT) hematocrit indicators by 5,8% (p = 0,3) in patients with II stage of CC and by 11,4% (p = 0,02) in patients with III stage of СС relative to baseline indices of CC-patients without LRC and were respectively 36,2% and 35,2%. Analysis of the level of fibrinogen showed that patients with II stage of СС this indicator before RT was statistically significant (p = 0,04) higher by 10.3% in patients with LRC and was 3,2 g/L, respectively. In patients with III stage of CC with LRC, the same indicator for RT was on the contrary lower by 8,3% (p = 0,5) relative to the indicators of patients without LRC. It was found that baseline AsAt in patients with СС was higher in patients with LRC, respectively, by 12,2% in patients with II stage of CC (p  0,05) and 18,5% (p < 0,01) in patients with III stage of CC. Noteworthy is the statistically probable (p < 0,05) increase in urea level in patients with CC after RP: by 25,6% in patients with II stage of СС and by 24,5% in patients with III stage of CC, which differs from the dynamics to a decrease in the same indicator in patients with cervical cancer without LRC (by 22,6% and 1,9% in patients with II and III stage of CC respectively). Characterizing the level of total protein in patients with II–III stage of CC it is worth noting that in patients with LRC, the baseline values of the indicated indicator are statistically significantly (p < 0,05) higher than the similar indicators of patients without LRC by 5,5% and 6,4%, respectively, in the II stage of CC and the III stage of CC.

Conclusions. Input indicators of hematocrit level in patients with III stage of CC with LRC statistically significant (p = 0,02) by 11,4% exceeded the corresponding figure in patients without LRC. The level of AsAt before RT in patients with III stage of CC with LRC statistically significantly (p < 0,01) exceeded by 18,5% the same indicator of patients without LRS, and after RT it tended to increase by 22,4%. It is established that patients with II and III stage of CC after RT, statistically significant (p < 0,05) increase of urea level by 25,6% and 24,5% respectively was noted.

References

Pak RV. Epidemiological features of cervical cancer in the world. Vestnik Kaz NMU. 2019; 1: 675–677.

Avinash HU, Arul Ponni TR, Janaki MG et al. A prospective dosimetric and clinical comparison of acute hematological toxicities in three-dimensional conformal radiation therapy and intensity modulated radiation therapy with concurrent chemotherapy in carcinoma cervix. J Cancer Res Ther. 2015; 11 (1): 83–87. DOI: 10.4103/0973-1482.151864.

Ioffe YJ, Hillen TJ, Zhou G et al. Postradiation damage to pelvic girdle in cervical cancer patients: is intensity-modulated radiation therapy safer than conventional radiation? J Gynecol Cancer., 2014; 24 (4): 806–812. DOI: 10.1097/IGC.0000000000000117.

Hladkykh FV, Kulinich HV. Assessment of risk factors for delayed radiation toxicity by combined surgical and radiation treatment in patients with cervical cancer. Ukrayinskyy medychnyy zhurnal. 2019; 5 (133): 18–22. DOI: 10.32471/umj.1680-3051.133.162492.

Erpolat OP, Alco G, Caqlar HB et al. Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study. Eur J Gynaecol Oncol. 2014; 35 (1): 62–66. DOI: 10.12892/ejgo23912014.

Lakosi F, de Cuypere M, Viet Nguyen P et al. Clinical efficacy and toxicity of radiochemotherapy and magnetic resonance imaging-guided brachytherapy for locally advanced cervical cancer patients: A mono-institutional experience. Acta Oncol. 2015; 54 (9): 1558–1566. DOI: 10.3109/0284186X.2015.1062542.

Krasnoselskyi MV, Hladkykh FV, Kulinich HV, Sevastianova VS. Clinicallaboratory portrait of patients with cervical cancer with late radiation toxicity due to radiation therapy. Medicni perspektivi. 2019; 24 (4): 121–133. DOI: 10.26641/2307-0404.2019.4.189603.

Hladkykh FV, Kulinich HV. Comparative characteristics of homeostatic shifts in patients with fibrotic and degenerative late radiation complications of radiation therapy for cervical cancer. Klinicheskaya Onkologiya. 2019; 4 (36): 1–7.

Hladkykh FV, Kulinich HV. Prognostic value of baseline hematologic and biochemical parameters in patients with cervical cancer with late radiation complications of cisplatin-based chemotherapy. Prakticheskaya onkologiya. 2019; 2 (3): 2–8. DOI: 10.22141/2663-3272.2.3.2019.186470.

Zar JH. Biostatistical analysis (5 ed.). Prentice-Hall, Englewood. 2014.

Misra S, Lal P, Kumar Ep S et al. Comparative assessment of late toxicity in patients with cervix carcinoma treated with radiotherapy versus chemo-radiotherapy – Minimum 5 years follow up. Cancer Treat Res Commun. 2018; 14: 30–36. DOI: 10.1016/j.ctarc.2017.11.007.

Hladkykh F. Pharmacoprophylactic and Pharmacotherapeutic Approaches to Mitigating the Damaging Effects of Ionizing Radiation: Review of Information Sources. Path of Science. 2018; 4 (12): 5001–5022. DOI: 10.22178/pos.41–5.

Published
2020-09-20
How to Cite
Sevastianova, V. S., Hladkykh, F. V., & Kulinich, H. V. (2020). Comparative characteristics of some haematological and biochemical indicators in II–III stages cervix cancer patients with late radiation complications in treatment dynamics. Modern Medical Technology, (3(46), 38-45. https://doi.org/10.34287/MMT.3(46).2020.7
Section
Original research